| Why carry out this study? |
| The clinical efficiency of cefoperazone/sulbactam (CPZ/SUL) against Escherichia coli bacteremia was unknown |
| What was learned from the study? |
| The activity of cefoperazone against cefoperazone-non-susceptible E. coli was restored upon combination with sulbactam, with susceptibility ranging from 0% to 97.7% |
| The overall clinical success rate was 91.9% (227/247) and the clinical success rate was 92.2% (226/245) among patients infected with E. coli bacteremia with CPZ/SUL MIC ≤16 mg/L |
| Heart failure, malignancy, SOFA score, and CPZ/SUL MIC ≥ 64 mg/L were independently associated with 30-day mortality |
| CPZ/SUL had a consistent clinical efficiency among patients with third-generation cephalosporin-non-susceptible E. coli bacteremia |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.